Multiple Myeloma

Several monoclonal antibodies with multiple myeloma cell antigen or bone marrow targets have exhibited strong antimyeloma activity and may become potential therapeutic agents.

Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.

The FDA has updated the label for pomalidomide plus low-dose dexamethasone for multiple myeloma to include data from the phase III MM-003 study.

The prospects for mAbs to change the treatment paradigm for multiple myeloma have grown considerably brighter as early-phase clinical trial results suggest that emerging agents with novel mechanisms of action are capable of delivering significant efficacy.

Ravi Vij, MD, associate professor, medicine, Division of Oncology, Section of Bone Marrow Transplant, Siteman Cancer Center, discusses the institution's tumor banking initiative for next-generation sequencing in multiple myeloma.

Sundar Jagannath, MD, discusses the latest research advances in myeloma, and how these steps will impact the future treatment paradigm for the disease.

An sNDA for the full approval of carfilzomib (Kyprolis) as a treatment for patients with relapsed multiple myeloma has been granted a priority review by the FDA.

The FDA has accepted a New Drug Application (NDA) for Captisol-enabled (CE) melphalan for the treatment of patients with multiple myeloma prior to autologous hematopoietic stem cell transplantation (AHCT).

OncLive interviewed Ravi Vij, MD, associate professor, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine and the Siteman Cancer Center, on what the future holds for stem cell transplantation in multiple myeloma.

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses immunotherapy in multiple myeloma and how it fits into the future treatment paradigm.

Carfilzomib doubled progression-free survival versus bortezomib in patients with relapsed multiple myeloma in the phase III ENDEAVOR trial.

The FDA has approved panobinostat in combination with bortezomib and dexamethasone for patients with previously treated multiple myeloma, based on findings from the PANORAMA-1 trial.

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens, according to Sundar Jagannath, MD.

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

The proteasome inhibitor ixazomib met its primary endpoint of improving progression-free survival at a prespecified interim analysis of a phase III trial of patients with relapsed/refractory multiple myeloma.

With the advent of safer and more effective treatments, early diagnosis of multiple myeloma (MM) has become an important goal.

Morie Gertz, MD, the chair of the Department of Medicine at the Mayo Clinic, discusses expanding treatment options for myeloma.

A supplemental New Drug Application has been submitted to the FDA for the full regulatory approval of carfilzomib as a treatment for patients with relapsed multiple myeloma.

A. Keith Stewart, MBChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years. Yet another revolution appears right around the corner.